The ability of HIV to mutate and reproduce itself in the presence of antiretroviral drugs is called HIV drug resistance (HIVDR). The consequences of HIVDR include treatment failure, need to start more costly second- and third- line treatments, increased health costs associated with these, spread of drug resistant HIV, and need to develop new anti-HIV drugs. WHO, and its partner organizations and experts of HIV ResNet group have developed a Global strategy for the surveillance and monitoring of HIV drug resistance. The strategy generates data on the emergence and transmission of HIVDR and equips countries with information to select first and second line antiretroviral therapy regimens.
Related Journals of Drug Resistance of HIV
Journal of Antivirals & Antiretrovirals, Journal of Infectious Diseases & Therapy, Virology & Mycology, Current HIV/AIDS Reports, AIDS Reader, AIDS Research and Therapy and Journal of the International AIDS Society.
Copyright: This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
To cite this article:
Jan 01, 1970
Accepted Date: Jan 01, 1970
Published Date: Jan 01, 1970